Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

K Kent ChevliNeal D ShoreAndrew TrainerAngela B SmithDaniel SaltzsteinYaron EhrlichJay D RamanBoris FriedmanRichard D'AnnaDavid MorrisBrian HuMark TysonAlexander SankinMax KatesJennifer LinehanDouglas ScherrSteven KesterMichael VerniKarim ChamieLawrence KarshArnold CinmanAndrew MeadsSoumi LahiriMadlen MalinowskiNimrod GabaiSunil RajuMark SchoenbergElyse SeltzerWilliam C Huang

Published in: The Journal of urology (2021)

Nonsurgical primary chemoablation of LG IR NMIBC using UGN-102 resulted in significant treatment response with sustained durability. UGN-102 may provide an alternative to repetitive surgery for patients with LG IR NMIBC.

Keyphrases

low grade
open label
muscle invasive bladder cancer
high grade
phase iii
phase ii
clinical trial
minimally invasive
study protocol
high frequency
coronary artery bypass
radiation therapy
coronary artery disease
phase ii study
rectal cancer